You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RET kinase

Showing 1 - 25 of 2,156
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

Recruiting
  • Malignant Thyroid Gland Neoplasm
  • +6 more
  • Quality-of-Life Assessment
  • +3 more
  • Ann Arbor, Michigan
  • +1 more
Jan 24, 2023

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 16, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +171 more
Aug 24, 2022

NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Brussels, Belgium
  • +18 more
Aug 23, 2022

Non Small Cell Lung Cancer Trial in United States (Ponatinib)

Completed
Has Results
  • Non Small Cell Lung Cancer
  • Orange, California
  • +4 more
Dec 8, 2019

Malignant Tumor Trial in Ann Arbor, Columbus (ponatinib HCl, laboratory biomarker analysis)

Unknown status
  • Malignant Neoplasm
  • ponatinib hydrochloride
  • laboratory biomarker analysis
  • Ann Arbor, Michigan
  • +1 more
Feb 14, 2020

Resistance-associated Mutations in Metastatic Lung Cancer

Recruiting
  • Lung Cancer
  • Liquid biopsy
  • Monza, MB, Italy
    Fondazione IRCCS San Gerardo dei Tintori
Oct 10, 2023

Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)

Recruiting
  • Medullary Thyroid Cancer
  • Birmingham, Alabama
  • +148 more
Jan 18, 2023

Metastatic Sporadic Medullary Thyroid Cancer Patients and

Completed
  • Metastatic Sporadic Medullary Thyroid Cancer
    • Milano, Italy
      Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Sep 29, 2021

    Irritable Bowel Syndrome Trial in Adelaide (GSK3352589, Matching Placebo)

    Completed
    Has Results
    • Irritable Bowel Syndrome
    • Adelaide, South Australia, Australia
      GSK Investigational Site
    Jun 28, 2019

    Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Singapore, Singapore
      Nationa University Hospital
    Jan 4, 2022

    ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

    Terminated
    Has Results
    • ALK-positive Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Irvine, California
    • +3 more
    Aug 30, 2021

    A Taiwanese Oncogenetic Panel and Integrated Clinical Data

    Recruiting
    • Thyroid Cancer
    • A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
    • Kaohsiung, Taiwan
    • +7 more
    Sep 12, 2022

    Biliary Tract Carcinoma Trial in Shanghai (Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab)

    Recruiting
    • Biliary Tract Carcinoma
    • Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Dec 25, 2022

    ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,

    Terminated
    Has Results
    • ALK Fusion Protein Expression
    • +14 more
    • San Francisco, California
      University of California, San Francisco
    Jan 14, 2020

    Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +44 more
    • Biopsy
    • +23 more
    • Birmingham, Alabama
    • +166 more
    Feb 2, 2023

    Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

    Not yet recruiting
    • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
    • Singapore, Singapore
      National Cancer Centre Singapore
    Oct 13, 2022

    Urothelial Cancer Trial in Spain (Niraparib plus Cabozantinib)

    Recruiting
    • Urothelial Cancer
    • Niraparib plus Cabozantinib
    • Barcelona, Cataluña, Spain
    • +10 more
    Feb 8, 2022

    Thyroid Carcinoma

    Recruiting
    • Differentiated Thyroid Carcinoma
    • Medullary Thyroid Carcinoma
    • Immunohistochemistry (IHC)
    • +2 more
    • L'Hospitalet De Llobregat, Barcelona, Spain
    • +11 more
    Mar 22, 2022

    Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

    Not yet recruiting
    • Breast Neoplasms
    • Hangzhou, Zhejiang, China
      ZhejiangCH
    Nov 17, 2023